Dr Bettina Wingelhofer, University of Manchester and John Goldman Fellow 2020

This research will help us understand how the complex network of interactions between enhancers and genes work, allowing us to identify novel regulators of acute myeloid leukaemia (AML) which could be used for therapeutic targeting with the aim of saving more patients from this devastating condition

What is this research looking at?

Acute myeloid leukaemia is driven by a distinct set of mutated genes which cause cells to multiply in an uncontrolled manner. However, mutations alone do not explain the activation or deactivation of certain critical genes important for the maintenance of AML cells. Instead, gene activity is influenced by stretches of DNA called enhancers located far away from their target gene. Dr Wingelhofer's goal is to investigate how these enhancers are activated, the network involved in their activation, and how they regulate the activity of their associated genes.

Official project title

Identification of leukaemia-specific functionally active enhancers for future therapeutic targeting in acute myeloid leukaemia

About Dr Wingelhofer

Dr Wingelhofer has been involved in haematology research over the last 6 years and is based at the University of Manchester.

The research findings that inspire Dr Wingelhofer are the emergence of treatments whose effectiveness can be traced back to a deep understanding of the biology of the cancer. Examples include the discovery of revolutionary treatments for CML and APL, which are now considered two of the most manageable forms of adult leukaemia. Dr Wingelhofer believes that with a deep understanding of the biology of AML we might be soon in a position where AML can be added to this list.

For Dr Wingelhofer, this funding has given her the opportunity to work on an original and innovative project, that could lead to exciting and important discoveries for the benefit of human knowledge and health. Being awarded a John Goldman Fellow is a significant steppingstone to help Dr Wingelhofer achieve her goal of running her own research group in leukaemia epigenetics.

We are able to fund vital research such as Dr Wingelhofer's project only thanks to the generosity of our supporters. 

With 27 people newly diagnosed with leukaemia every day in the UK, we strive to find better treatments and care to make a difference to those affected by blood cancers.

Find out more about our other ground-breaking research and care projects

Read about our prestigious John Goldman Fellowships

Donate now to help us make a difference